REIG JOFRE submits press release on the global license agreement reached by Syna Therapeutics

REIG JOFRE, pharmaceutical company listed on the Spanish stock exchange established in 2018 the joint-venture Syna Therapeutics, 50% owned by LeanBio and REIG JOFRE, for the development of biopharmaceutical products in the field of biosimilars and innovative molecules. After 4 years, Syna Therapeutics has just signed an exclusive license agreement with Intas Pharmaceuticals Ltd. (“Intas”) and its wholly owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702.

Andreu Soldevila, CEO of Syna, Gabriel Roig, chairman of the Syna Board, and Isabel Amat, member of the Syna Board

According to the terms of the agreement, Syna Therapeutics will begin in 2023 the clinical trials for its biosimilar LB-07802 to treat pathologies in the field of hematology. For its part, Intas Pharmaceutical Ltd., a global biopharmaceutical company, will cover the marketing costs. Intas currently has one of the largest sales, marketing, and distribution networks for biosimilars in the world, particularly to hospitals, with a presence in 85 countries.

REIG JOFRE will contribute to the development and stabilization of the final pharmaceutical product, besides offering its first-rate global production capacity in its new development and specialized production center in Barcelona, which after an investment of €40 million completed in 2021, has state-of-the-art technology and the highest quality standards for sterile injectables and lyophilized biopharmaceutical products, with an annual capacity of up to 45 million lyophilized aseptic vials and 50 million liquid solution vials.

REIG JOFRE thus contributes to a greater integration of the biological drug development and manufacturing process, uniting through Syna Therapeutics the development of the active ingredient and the production of the final biopharmaceutical product.

Download the full document (PDF)